Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway
Authors:
Open Access
- 10 December 2025
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (2) , 477-490
Abstract
Introduction Routine childhood immunization programs using pneumococcal conjugate vaccines (PCVs) significantly reduce the burden of pneumococcal disease (PD). PCV21, a 21-valent PCV, was recently approved and recommended by the European Commission for use in Norway. The objective of this study was to quantify the health and economic burden of invasive PD (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) attributable to PCV21, PCV20, and PPSV23 serotypes among adults in Norway. Methods A published Markov model was adapted to estimate lifetime IPD/NBPP cases, deaths, and direct medical costs (in 2023 Norwegian kroner [NOK]) associated with PCV21, PCV20, and PPSV23 serotypes in Norway. Results were disaggregated by age and risk groups. A one-way sensitivity analysis examined changes in disease costs (± 20%). Results The projected number of PD cases and deaths attributable to PCV21 serotypes was substantially higher than those attributable to PCV20 and PPSV23 serotypes. PD cases and deaths attributable to PCV21 serotypes vs. PCV20 and PPSV23 were ~ 41% and ~ 26% higher, respectively, in adults aged 65+ years, ~ 39% and ~ 25% higher in those aged 50–64 years, and ~ 37% and ~ 22% higher in those aged 18–64 years with risk factors. Within each age group, cases and total lifetime costs increased progressively as risk categorization increased. Estimated lifetime direct treatment costs for PD attributable to PCV21 serotypes were higher than those associated with PCV20 or PPSV23, at 3.9 billion NOK, 3.5 billion NOK, and 4.4 billion NOK in adults aged 65+, 50–64, and 18–64 years with risk factors, respectively. Conclusions Compared with PCV20 and PPSV23, PCV21 serotypes are associated with a higher health and economic burden in Norway. The inclusion of PCV21 into national vaccine recommendations in Norway can further alleviate the burden associated with PD in adults.Keywords
Funding Information
- Merck
This publication has 27 references indexed in Scilit:
- Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United StatesInfectious Diseases and Therapy, 2024
- Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United StatesInfectious Diseases and Therapy, 2024
- Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settingsVaccine, 2024
- Clinical and economic burden of invasive pneumococcal disease and noninvasive all-cause pneumonia in hospitalized US adults: A multicenter analysis from 2015 to 2020International Journal of Infectious Diseases, 2024
- Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE StudyInternational Journal of Infectious Diseases, 2022
- The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in AustraliaVaccine, 2018
- Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United StatesJournal of General Internal Medicine, 2016
- Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in NorwayVaccine, 2013
- Healthcare utilization and cost of pneumococcal disease in the United StatesVaccine, 2011
- The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysisJournal of Infection, 2010